User login
Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.
Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P = .0003) and PFS (aHR 0.70; P = .0001) even after confounder adjustment.
Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.
Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.
Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi: 10.1002/ijc.34166
Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.
Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P = .0003) and PFS (aHR 0.70; P = .0001) even after confounder adjustment.
Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.
Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.
Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi: 10.1002/ijc.34166
Key clinical point: Second-line fluorouracil-leucovorin-irinotecan (FOLFIRI)-bevacizumab is associated with a longer overall survival (OS) and progression-free survival (PFS) and better tolerance than FOLFIRI-aflibercept in patients with metastatic colorectal cancer (mCRC) after progression on fluorouracil-leucovorin-oxaliplatin (FOLFOX)-bevacizumab.
Major finding: After a 31.2-month median follow-up, the FOLFIRI-bevacizumab vs FOLFIRI-aflibercept group had a significantly longer median OS (13.0 vs 10.4 months; P < .0001) and PFS (6.01 vs 5.09 months; P < .0001) and a lower grade 3-4 toxicity rate (P < .0001), with bevacizumab being associated with better OS (adjusted hazard ratio [aHR] 0.71; P = .0003) and PFS (aHR 0.70; P = .0001) even after confounder adjustment.
Study details: Findings are from a retrospective, real-world cohort study, BEFLICO, that included 681 patients with mCRC who received FOLFIRI-aflibercept (n = 326) or FOLFIRI-bevacizumab (n = 355) in the second-line setting.
Disclosures: This study was supported by the Association des Gastro-entérologues Oncologues (AGEO). Some authors reported receiving speaker/advisor honoraria, consulting/personal fees, and/or research/travel funding from various sources.
Source: Torregrosa C et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022 (Jun 15). Doi: 10.1002/ijc.34166